Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
Oramed Pharmaceuticals (NASDAQ: ORMP) said it will be added to the Russell 2000 and Russell 3000 indexes after the 2026 semi-annual reconstitution, effective at the market open June 29, 2026. FTSE Russell’s preliminary additions were posted May 22, with final changes after June 26 close. Russell membership can also trigger inclusion in Russell 1000/2000 and style indexes, according to FTSE Russell.
How this was made
The 30-second read
Why it matters
The key tradable element is the scheduled passive rebalancing window tied to Russell 2000/3000 inclusion, which can affect demand for ORMP shares around the effective date.
Market read
This is a mechanical index-constituent event for ORMP with a clear effective date, relevant for short-term flow/volatility trading.
What to watch
Actual impact depends on Oramed’s index weight, passive AUM tracking Russell, liquidity, and whether the stock is already widely held by Russell-tracking funds.
Background
Russell semi-annual reconstitution updates membership based on market-cap rankings as of April 30, with changes effective after the June 26 close.
Ticker impact
Oramed Pharmaceuticals said it will be added to the Russell 2000 and Russell 3000 at the June 29 effective date after the June 26 close.
Likely short-term volatility and modest directional pressure around reconstitution, with magnitude dependent on passive ownership and liquidity.
The article discloses a specific, time-bound index change (effective June 29) but provides no fundamentals, guidance, or deal economics.
Market effects
Small-cap biotech/specialty pharma names can see correlated flow effects during Russell reconstitution, but this is company-specific.
Primarily US passive/benchmark flows; limited direct impact on non-US listings beyond sentiment.
Russell index changes are widely tracked by global ETF investors, but the effect is typically localized to affected constituents.
Counterpoint
Index additions often fade quickly after reconstitution; any price move may be fully anticipated by the market before the effective date.
Key entities
- companyOramed Pharmaceuticals Inc.
Set to join Russell 2000 and Russell 3000 at the 2026 semi-annual reconstitution effective June 29.
- index_providerFTSE Russell
Publishes the preliminary additions list and finalizes reconstitution after the June 26 close.
